Cardiologic complications of acromegaly


Cite item

Full Text

Abstract

A frequent complication of acromegaly in any age patients is akromegalic cardiomyopathy, characterized by the formation of left ventricle myocardial hypertrophy (LVMH), and the occurrence of heart rhythm disorders. In cases with no adequate controls of hormonal disturbances in acromegaly, cardiomyopathy leads to the formation of diastolic heart failure. Surgical and pharmacological (using somatostatin analogues) treatment of acromegaly leads to the improvement of the heart condition and regress LVMH, especially in young patients (younger than 40 years) with a small duration of disease (no more than 5 years). Meaningful morpho-functional and hemodynamic parameters improvement observed in middle-aged patients.

About the authors

I A Ilovayskaya

I A Ilovayskaya

References

  1. Colao A, Marzullo P, Di Somma C, et al. Growth hormone and the heart. Clin Endocrinol 2001; 54:137-154.
  2. Colao A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Colao%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol <javascript:AL_get(this,%20'jour',%20'Clin%20Endocrinol%20(Oxf).');>2008;69(3):347-358.
  3. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89(2):667-674.
  4. Huchard H. Anatomie pathologique, lesions et trouble cardiovasculaires de l'acromegalie. J Practiciens 1895;9:249-250.
  5. Minniti G, Jaffrain-Rea ML, Moroni C, et al. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol 1998;49:101-106.
  6. Fazio S, Cittadini A, Sabatini D, et al. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study. Eur Heart J 1993;14:26-33.
  7. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999;341: 1276-1283.
  8. Белова Ю.Ю., Марова Е.И., Шамарин В.М. и др. Патология сердечно-сосудистой системы при акромегалии // Проблемы эндокринологии. <http://ucm.sibtechcenter.ru/?query=rec.id%3D%22%D0%9F230180%22&sortKeys=none&startRecord=1&maximumRecords=5&recordSchema=marcxml&recordPacking=xml&mode=standard> 2004. -Т. 50. № 2. С. 3947 <http://ucm.sibtechcenter.ru/?query=rec.id%3D%22%D0%9F230180%2F2004%2F50%2F2%22&sortKeys=none&startRecord=1&maximumRecords=5&recordSchema=marcxml&recordPacking=xml&mode=standard>.
  9. Colao A, Ferone D, Marzullo P, et al. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocrine Reviews 2004;25(1):102-152.
  10. Lie JT, Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 1980;100:41-52.
  11. Fazio S, Cittadini A, Biondi B, et al. Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metab 2000;85:179-182.
  12. Colao A, Spinelli L, Cuocolo A, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 2002;87:3097-3104.
  13. Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000;85:193-199.
  14. López-Velasco R, Escobar-Morreale HF, Vega B, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension. J Clin Endocrinol Metab 1997;82:1047-1053.
  15. Ferrari AU. Modifications of the cardiovascular system with aging. Am J Geriatr Cardiol 2002;11:30-33.
  16. Kahaly G, Olshausen KV, Mohr-Kahaly S, et al. Arrhythmia profile in acromegaly. Eur Heart J 1992;13:51-56.
  17. Cable DG, Dearani JA, O'Brien T, et al. Surgical treatment of valvular heart disease in patients with acromegaly. J Heart Valve Dis 2000;9:828-831.
  18. Colao A, Spinelli L, Marzullo P, et al. High prevalence of cardiac valve disease in acromegaly: an observational analytical prospective case-control study. J Clin Endocrinol Metab 2003;88:3196-3201.
  19. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 1995;30:825-834.
  20. Wahlander H, Isgaard J, Jennische E, et al. Left ventricular insulin-like growth factor-I increases in early renal hypertension. Hypertension 1992;19:25-32.
  21. Cittadini A, Stromer H, Katz SE, et al. Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat. A combined in vivo and in vitro evaluation. Circulation 1996;93:800-809.
  22. Freestone NS, Ribaric S, Mason WT. The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol Cell Biochem 1996;163:223-229.
  23. Frustaci A, Chimenti C, Setoguchi M, et al. Cell death in acromegalic cardiomyopathy. Circulation 1999;99:1426-1434.
  24. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
  25. Gatford KL, Egan AR, Clarke IJ, et al. Sexual dimorphism of the somatotrophic axis. J Endocrinol 1998;157:373-389.
  26. Parkinson C, Renehan AG, Ryder WD, et al. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol 2002;57:59-64.
  27. Colao A, Cuocolo A, Marzullo P, et al. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. J Clin Endocrinol Metab 1999;84:1518-1523.
  28. Boero L <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Boero%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Manavela M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Manavela%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Rosso LG <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Rosso%20LG%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly. Clin Endocrinol <javascript:AL_get(this,%20'jour',%20'Clin%20Endocrinol%20(Oxf).');> 2009;70(1): 88-95.
  29. Kahaly G, Olshausen KV, Mohr-Kahaly S, et al. Arrhythmia profile in acromegaly. Eur Heart J 1992;13:51-56.
  30. Kozer LM, Cheriparambil KM, Schifter DR, et al. Clinical significance of variability of ventricular late potentials detected before discharge in patients after myocardial infarction. Am Heart J 2000;139:134-141.
  31. Herrmann BL, Bruch C, Saller B, et al. Occurrence of ventricular late potentials in patients with active acromegaly. Clin Endocrinol 2001;55:201-207.
  32. Pietrobelli DJ, Akopian M, Olivieri AO, et al. Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J Hum Hypertens 2001;15:601-605.
  33. Jaffrain-Rea ML, Moroni C, Baldelli R, et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol 2001;54:189-195.
  34. Colao A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Colao%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Terzolo M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Terzolo%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Bondanelli M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bondanelli%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol <javascript:AL_get(this,%20'jour',%20'Clin%20Endocrinol%20(Oxf).');>2008;69(4):613-20.
  35. Ritchie CM, Sheridan B, Fraser R, et al. Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. Q J Med 1990;76:855-867.
  36. Chanson P, Megnien JL, del Pino M, et al. Decreased regional blood flow in patients with acromegaly. Clin Endocrinol 1998;49:725-731.
  37. Deray G, Chanson P, Maistre G, et al. Atrial natriuretic factor in patients with acromegaly. Eur J Clin Pharmacol 1990;38:409-413.
  38. Bates AS, Van't Hoff W, Jones JM, et al. An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293-299.
  39. Swearingen B, Barker FGII, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-3426.
  40. Minniti G, Moroni C, Jaffrain-Rea ML, et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol 2001;55:307-313.
  41. Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab 2001;86: 1551-1557.
  42. Tokgözoglu SL, Erbas T, Aytemir K, et al. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol 1994;74:1072-1074.
  43. Merola B, Cittadini A, Colao A, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993;77: 790-793.
  44. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990;113: 921-925.
  45. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000;86: 3132-3140.
  46. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue Octreotide. Clin Endocrinol 2003;58: 169-176.
  47. Maison P <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Maison%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Tropeano AI <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tropeano%20AI%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Macquin-Mavier I <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Macquin-Mavier%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab <javascript:AL_get(this,%20'jour',%20'J%20Clin%20Endocrinol%20Metab.');> 2007;92(5):1743-1747.
  48. Damjanovic SS <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Damjanovic%20SS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Neskovic AN <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Neskovic%20AN%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Petakov MS <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Petakov%20MS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clin Endocrinol <javascript:AL_get(this,%20'jour',%20'Clin%20Endocrinol%20(Oxf).');>2005;62(4):410-417.
  49. Colao A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Colao%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Pivonello R <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pivonello%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Galderisi M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Galderisi%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab <javascript:AL_get(this,%20'jour',%20'J%20Clin%20Endocrinol%20Metab.');> 2008;93(7):2639-2646.
  50. Lombardi G, Colao A, Marzullo P, et al. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced growth hormone and insulin-like growth factor-I decrease in acromegaly: a prospective multicenter study. J Endocrinol Invest 2002;25:971-976.
  51. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2321&mid=1085056570&magid=174&full=1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies